Switzerland's Basilea H1 revenue rises on Cresemba demand; ups 2026 profit outlook

Basilea Pharmaceutica AG, Allschwil

18/08/2026 06:26

Overview
Switzerland biopharma firm's H1 2026 revenue grew 14% yr/yr to CHF 119 mln
Operating profit for H1 2026 rose 32% yr/yr, net profit up 77%
Company raised FY 2026 guidance, now expects 40% operating profit growth

Outlook
Basilea raises 2026 operating profit growth guidance to ~40%, up from ~20% previously
Company now expects 2026 total revenue to increase by ~15%, versus ~10% previously
Cresemba and Zevtera-related revenue expected to reach CHF ~210 mln in 2026

Result Drivers
CRESEMBA DEMAND - Co said continued strong market demand for Cresemba drove royalty income and supported revenue growth
EXTERNAL FUNDING - Revenue from BARDA and CARB-X contracts increased, supporting late- and early-stage R&D programs
COST OF PRODUCTS SOLD - Lower cost of products sold contributed to improved profitability

Company press release: ID:nGNE5ZWzfw

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 EPS
 
CHF 2.13
 
H1 Net Income
 
CHF 27.90 mln
 
H1 Basic EPS
 
CHF 2.26
 
H1 Operating Expenses
 
-CHF 87.40 mln
 
H1 Operating Income
 
CHF 31.60 mln
 
H1 Pretax Profit
 
CHF 32.10 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Basilea Pharmaceutica AG, Allschwil is CHF105.00, about 93.7% above its August 17 closing price of CHF54.20
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 11 three months ago

Reuters Recommended Reads
Aug 17 - Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Aug 18 - Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast 
Aug 17 - China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)